Medical Access in Kuwait

Currently classified as a strictly controlled substance under Kuwait’s unified narcotics/psychotropics legislation with no authorised medical use outside approved clinical research. Possession, importation, or handling outside Ministry‑authorised research and licensing carries severe penalties under the new anti‑narcotics law. [1]Meysan legal note on Kuwait Narcotics Law [2]HFW briefing on Kuwait Anti‑Drug Law.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Handling, possession or distribution outside Ministry authorisations risks severe criminal sanctions under Decree‑Law No. 159/2025. [1]Meysan legal note on Kuwait Narcotics Law.

No public record of a national marketing authorisation or inclusion in publicly reimbursed formularies for esketamine (Spravato®) in Kuwait as of Feb 20, 2026; availability therefore appears limited or absent and would require Ministry of Health special licensing/import authorisation for any use. Kuwait’s new anti‑narcotics framework and recent ministerial rules impose strict documentary and prescription requirements for any narcotic/psychotropic entry or supply, which would apply to any esketamine importation or use if authorised. Clinicians or institutions wishing to use esketamine would need Ministry approval and must comply with the special prescription, short dispensing windows and digital recordkeeping obligations set out in the law. [1]Meysan legal note on Kuwait Narcotics Law [2]HFW briefing on Kuwait Anti‑Drug Law.

Ketamine is an established, authorised medicine in Kuwait for anaesthesia, emergency sedation and other approved clinical uses and is used in hospital emergency and peri‑operative protocols; it remains subject to strict Ministry of Health controls for prescribing, storage and reporting under the new narcotics law. Clinical usage: Kuwaiti hospital emergency and pediatric clinical protocols list ketamine for induction, sedation and emergency airway management (local emergency/pediatric clinical guidance includes ketamine dosing and indications). [1]Kuwait Emergency Pediatric Booklet 2023–2024. Regulatory framework and supply controls: Decree‑Law No. 159/2025 centralises regulation of narcotic and psychotropic substances, requires Ministry‑approved special prescription forms, tight limits on dispensing quantities and strict 24‑hour/quarterly digital inventory and reporting for healthcare facilities and pharmacies; these requirements apply to ketamine where it is controlled as a narcotic/psychotropic for supply‑chain purposes. Implementation consequences: hospitals, pharmacies and prescribers must keep original prescriptions, enter transactions into Ministry‑approved registers within 24 hours, and comply with short prescription validity and limited refill windows unless a ministerial exception is obtained. Reimbursement: public reimbursement details are not published centrally; ketamine is used in public hospitals for anaesthesia/acute care (WHO lists ketamine on the Model List of Essential Medicines, supporting its role in essential clinical services), but routine outpatient or psychopharmacological ketamine infusion programs (for psychiatric indications) would require high‑level Ministry approvals, specialised licensing and would be constrained by the new law’s dispensing and reporting regime. [2]Meysan legal note on Kuwait Narcotics Law [3]WHO Model List of Essential Medicines (2023) [1]Kuwait Emergency Pediatric Booklet 2023–2024.

Currently classified as a strictly controlled substance under the national drug schedule and the 1971 Convention on Psychotropic Substances; no authorised medical access outside approved clinical research in Kuwait. Possession, importation or use outside Ministry‑approved research or licencing is subject to severe penalties under Decree‑Law No. 159/2025. [1]Meysan legal note on Kuwait Narcotics Law.

Currently classified as a strictly controlled substance under Kuwait’s narcotics and psychotropics law, with no authorised medical use outside approved clinical research. Handling outside Ministry authorisation carries significant criminal and administrative penalties per Decree‑Law No. 159/2025. [1]Meysan legal note on Kuwait Narcotics Law.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Importation, possession or use without Ministry approval is punishable under the unified anti‑narcotics law. [1]Meysan legal note on Kuwait Narcotics Law.

Ayahuasca preparations contain DMT (a controlled psychotropic); such preparations are effectively prohibited for non‑research use in Kuwait and are subject to the same tight import, possession and supply controls as other psychotropic substances under Decree‑Law No. 159/2025. No authorised medical or religious exemptions have been published for Kuwait. [1]Meysan legal note on Kuwait Narcotics Law.

Mescaline is classified as a controlled psychotropic/narcotic under Kuwait’s unified anti‑narcotics framework and has no authorised medical use outside Ministry‑approved research; cacti containing mescaline would be controlled to the extent their psychotropic content is relevant under the new law. Unauthorized possession, importation or distribution risks severe criminal penalties. [1]Meysan legal note on Kuwait Narcotics Law.

Phenethylamine '2C' family compounds are controlled under Kuwait’s psychotropic/narcotics law; there is no authorised medical use and no routine medical reimbursement — possession or distribution outside authorised research is subject to criminal penalties under Decree‑Law No. 159/2025. [1]Meysan legal note on Kuwait Narcotics Law.